Proactive Investors - Run By Investors For Investors

Silence Therapeutics promotes Sedgwick to CEO role; Christély resigns

Silence Therapeutics promotes Sedgwick to CEO role; Christély resigns

Gene silencing specialist Silence Therapeutics (LON:SLN) announced today that Tony Sedgwick has been appointed the new CEO of the company following the resignation of Thomas Christély.

Sedgwick was formerly the chief business officer and his promotion takes effect immediately, the firm said.

Christély has resigned as a director for personal reasons but will ensure a smooth transition, the company added.

The company's chairman Jerry Randall said: "Tony has a great deal of relevant experience gained from the global pharmaceutical industry. He has made a very positive impact on Silence since joining in September last year and has demonstrated the right leadership skills needed as the company continues to gain momentum."

He thanked Christély for his many years of valuable service, on behalf of the board, and wished him well for the future.

New chief executive Sedgwick said that since joining the company, he had been excited about the opportunities ahead.

"We have already strengthened the business development team with the appointment of Dr Georg Buchner who will now take full responsibility for business development.

"The company's pipeline including Atu027 is making good progress and is endorsed by external partners," he said.

He added that in the next few years, he planned to increase the commercial focus of the company.

The company develops siRNAs, which are double-stranded molecules that silence certain genes. These are being developed to be used in targeting multiple disease types, including cancer.

Last month, the company announced a collaboration agreement with
US–based firm miRagen to assess delivery methods for new, micro versions of gene silencing technology to treat serious diseases.

Why Invest In Silence Therapeutics plc? Read More Here

Register here to be notified of future SLN Company articles
View full SLN profile

Silence Therapeutics plc Timeline

September 27 2016
January 18 2016

Related Articles

drug resistant infections such as E. coli and Pseudomonas
October 02 2016
In vivo testing confirmed that Redx’s novel compounds were highly effective against certain drug resistant strains of bacteria.
May 02 2016
As UK biotechs are beating a trail to the US craving greater understanding and higher valuation, Doerfler and his team have opted to go in the opposite direction.
March 01 2016
Lupuzor is not the only part of the Immupharma story and McCarthy plans also to raise the profile of the rest of the group's early stage pipeline in 2016.....

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.